Abstract
Detailed knowledge of the properties of exhaled particles from the human respiratory tract for all genders and ages is essential to determine the modes of transmission of airborne diseases. This applies not only to the current COVID-19 pandemic, but also to many others, be it measles, seasonal influenza or tuberculosis. To date, there are no data on the individual-specific concentrations and sizes of exhaled particles over the entire size range from nanometre to millimetre. Here we present a comprehensive data set, measured by particle size spectrometry and in-line holography covering the entire size range from 132 healthy volunteers aged 5 to 80 years for a defined set of breathing and vocalisation activities. We find age to have a large effect on small particle concentrations (<5 µm), doubling in children during adolescence and in adults over a 30-year period. In contrast, gender, body mass index, smoking or exercise habits have no discernible influence. Particles >20 µm show on average no measurable dependence on the type of vocalisation with the exception of shouting. We show evidence that particles <5 µm mainly originate in the lower respiratory tract, 5-15 µm in the larynx/pharynx, and >15 µm in the oral cavity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work has been funded by the BMBF (Federal Ministry of Education and Research) as part of the B-FAST (Bundesweites Forschungsnetz Angewandte Surveillance und Testung) project (01KX2021) within the NUM (Netzwerk Universitatsmedizin), Deutsche Forschungsgemeinschaft (project number: 469107130) and the Max Planck Society. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The non-invasive exhaled aerosol sampling study which led to this paper was approved by the Ethics Commission of the Max Planck Society (Submission 2020 23). All subjects gave their written consent to data storage and analysis.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is available upon reasonable request and after acceptance of open data repositories and on aerosol.ds.mpg.de
